Return to Listing

2 result(s) for BKM120

PI Name Protocol # Title
Robert Raish IRB00009076 A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment
Matthew Taylor IRB00010122 CBKM120ZUS40: Modular Phase 2 Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 1 - BKM120 for Patients with PI3K-activated Tumors
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080

You may qualify for additional trials within our Phase 1 Program